Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit
NCT02757625
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Subjects whose consent is obtained in writing prior to the clinical trial from a guardian after a full explanation. For subjects over 7 years old, it is desirable that an informed assent is also obtained from the pediatric subject him/herself when possible.
2. Subjects aged ≥45 weeks CGA to <17 years old at time of consent. No restriction on sex of subject.
3. [Elective surgical cases] Subjects classified as American Society of Anesthesiologists (ASA) (ASA physical status classification) Class I to III by preoperative diagnosis.
4. [Elective surgical cases] Subjects who require at least 6 hours of respiratory management with intubation under intensive care from immediately after surgery and are anticipated to require sedation.
5. [Medical ICU cases] Subjects who require at least 24 hours of respiratory management with intubation under intensive care and are anticipated to require sedation. For medical ICU cases, sedatives used prior to treatment with the investigational product should be discontinued before the start of treatment with the investigational product.
6. If a subject is a female of childbearing potential, she should not be pregnant or possibly pregnant, or lactating.
1. Subjects who are judged by investigator or sub-investigator to have a neurological
disease that will make sedation assessment difficult, such as:
- Subjects with brain damage which is expected to increase intracranial pressure
due to trauma or central nervous system disease
- Subjects with cerebral palsy, autism, severe mental retardation, etc.
- Subjects with paralysis due to continuous administration of a muscle relaxant or
due to a spinal injury of class T5 or higher.
2. Subjects with 2nd or 3rd degree heart block during the tests at the screening visit
(excluding subjects using a pacemaker).
3. Subjects with any of the following low blood pressure levels during the tests at the
screening visit:
- Age ≥ 45 weeks CGA to < 1 year old: Systolic Blood Pressure (SBP) <70 mmHg
- Age ≥ 1 year old to < 10 years old: SBP < 70 + (2 x age in years) mmHg
- Age ≥ 10 years old to < 17 years old: SBP < 90 mmHg
4. Subject of bradycardia (≤10th centile of heart rate for healthy children) during the
physical examination at screening period.
5. Subjects with ALT ≥100 U/L during the laboratory tests at the screening visit.
6. Subjects in whom dexmedetomidine or other alfa 2 receptor agonists, alfa 2 receptor
antagonists and drug that may be used in this study are contraindicated.
7. Subjects who may need a sedative or analgesic (including narcotics) other than
dexmedetomidine, midazolam or fentanyl during treatment with the investigational
product.
8. Subjects who have acute febrile illness [with a temperature (core or tympanic) ≥
38.0°Centigrade] at the screening visit.
9. Subjects who received other investigational product within 30 days before baseline or
subjects who will participate in other study that uses an investigational product
during the study period.
10. Subjects who received dexmedetomidine within 48 hours before baseline.
11. Subjects who, in the opinion of the investigator or sub-investigator, may be at
increased risk to the subject due to the conduct of the study or may have a disease or
factor which will probably preclude the obtainment of sufficient study data.
12. Subjects for whom, in the opinion of the investigator or sub-investigator, risks
involved with administration of dexmedetomidine outweigh its benefits (e.g., >2 doses
of vasopressor due to cardiogenic shock).
13. Subjects who are investigational site staff members directly involved in the conduct
of the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are Sponsor's employees directly involved in the conduct
of the study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Asahikawa, Hokkaido
- Kobe, Hyogo
- Zentsuji, Kagawa
- Izumi, Osaka
- Takatsuki, Osaka
- Shimotsuke, Tochigi
- Bunkyo-ku, Tokyo
- Fuchu, Tokyo
- Kyoto,
- Okayama,
- Osaka,
- Shizuoka,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit | |||
Official Title ICMJE | Phase 3, Multi-center, Single-arm, Open-label Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Da-9501 (Dexmedetomidine Hydrochloride) In Pediatric Subjects In The Intensive Care Unit | |||
Brief Summary | To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects [? 45 weeks CGA (corrected gestational age) to <17 years old] requiring sedation under intensive care unit | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | ICU Sedation | |||
Intervention ICMJE | Drug: Dexmedetomidine hydrochloride
| |||
Study Arms ICMJE | Experimental: DA-9501
A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline Intervention: Drug: Dexmedetomidine hydrochloride | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 63 | |||
Original Estimated Enrollment ICMJE | 60 | |||
Actual Study Completion Date ICMJE | May 24, 2017 | |||
Actual Primary Completion Date | May 24, 2017 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 45 Weeks to 16 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02757625 | |||
Other Study ID Numbers ICMJE | C0801017 ZIN-DEX-1506 ( Other Identifier: Alias Study Number ) | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Maruishi Pharmaceutical | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | May 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |